Next 10 |
2024-07-29 07:15:06 ET Barclays analyst issues OVERWEIGHT recommendation for MGNX on July 29, 2024 05:41AM ET. The previous analyst recommendation was Overweight. MGNX was trading at $5.55 at issue of the analyst recommendation. The overall analyst consensus : BUY. C...
2024-07-29 07:00:10 ET Peter Lawson from Barclays issued a price target of $9.00 for MGNX on 2024-07-29 05:41:00. The adjusted price target was set to $9.00. At the time of the announcement, MGNX was trading at $5.55. The overall price target consensus is at $15.43 with ...
MacroGenics, Inc. (NASDAQ: MGNX) is the focus of IBN's latest stock spotlight. The company's shares have moved 1.9% on the day to $5.35. MacroGenics, Inc., a biopharmaceutical company, develops and commercializes antibody-based therapeutics to treat cancer in the United States. Its approved pr...
MacroGenics, Inc. (NASDAQ: MGNX) is the focus of IBN's latest stock spotlight. The company's shares have moved 1.07% on the day to $4.7. MacroGenics, Inc., a biopharmaceutical company, develops and commercializes antibody-based therapeutics to treat cancer in the United States. Its approved pr...
2024-05-23 20:30:04 ET BTIG analyst issues BUY recommendation for MGNX on May 23, 2024 06:39PM ET. The previous analyst recommendation was Buy. MGNX was trading at $4.63 at issue of the analyst recommendation. The overall analyst consensus : BUY. Current analyst reco...
2024-05-23 20:00:06 ET Kaveri Pohlman from BTIG issued a price target of $9.00 for MGNX on 2024-05-23 18:39:00. The adjusted price target was set to $9.00. At the time of the announcement, MGNX was trading at $4.63. The overall price target consensus is at $15.00 with hi...
2024-05-20 00:00:02 ET Citigroup analyst issues BUY recommendation for MGNX on May 18, 2024 12:04PM ET. The previous analyst recommendation was Buy. MGNX was trading at $4.365 at issue of the analyst recommendation. The overall analyst consensus : BUY. Current analys...
2024-05-14 08:25:47 ET More on pre-market losers & stocks. MacroGenics: Strong Likelihood Bad News Has Caused Overreaction (Rating Upgrade) AppLovin: Remains A 'Strong Buy' After Post-Earnings Surge (SA Quant) MacroGenics, Inc. (MGNX) Q1 2024 Earnings Call Transc...
The law firm of Kirby McInerney LLP is investigating potential claims against MacroGenics, Inc. (“MacroGenics” or the “Company”) (NASDAQ: MGNX ). The investigation concerns whether MacroGenics and/or certain of its officers have violated the federal securities ...
2024-05-13 13:30:51 ET More on mid-day movers & stocks. CareCloud, Inc. (CCLD) Q4 2023 Earnings Call Transcript Faraday Future announces Nasdaq delisting determination Faraday Future Intelligent Electric receives Nasdaq non-compliance letter Seeking Alpha...
News, Short Squeeze, Breakout and More Instantly...
2024-07-29 07:15:06 ET Barclays analyst issues OVERWEIGHT recommendation for MGNX on July 29, 2024 05:41AM ET. The previous analyst recommendation was Overweight. MGNX was trading at $5.55 at issue of the analyst recommendation. The overall analyst consensus : BUY. C...
2024-07-29 07:00:10 ET Peter Lawson from Barclays issued a price target of $9.00 for MGNX on 2024-07-29 05:41:00. The adjusted price target was set to $9.00. At the time of the announcement, MGNX was trading at $5.55. The overall price target consensus is at $15.43 with ...
MacroGenics, Inc. (NASDAQ: MGNX) is the focus of IBN's latest stock spotlight. The company's shares have moved 1.9% on the day to $5.35. MacroGenics, Inc., a biopharmaceutical company, develops and commercializes antibody-based therapeutics to treat cancer in the United States. Its approved pr...